{"name":"Nuvation Bio Inc.","slug":"nuvation-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AB-106, Rifampicin","genericName":"AB-106, Rifampicin","slug":"ab-106-rifampicin","indication":"Tuberculosis","status":"phase_1"},{"name":"AB-106, Itraconazole","genericName":"AB-106, Itraconazole","slug":"ab-106-itraconazole","indication":"Fungal infections","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"DS6051b","genericName":"DS6051b","slug":"ds6051b","indication":"Other","status":"phase_1"},{"name":"NUV-1511","genericName":"NUV-1511","slug":"nuv-1511","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AB-106","genericName":"AB-106","slug":"ab-106","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"AB-106, digoxin","genericName":"AB-106, digoxin","slug":"ab-106-digoxin","indication":"Atrial fibrillation","status":"phase_1"}]}],"pipeline":[{"name":"AB-106","genericName":"AB-106","slug":"ab-106","phase":"phase_2","mechanism":"AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"AB-106, Rifampicin","genericName":"AB-106, Rifampicin","slug":"ab-106-rifampicin","phase":"phase_1","mechanism":"Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase","indications":["Tuberculosis"],"catalyst":""},{"name":"DS6051b","genericName":"DS6051b","slug":"ds6051b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB-106, Itraconazole","genericName":"AB-106, Itraconazole","slug":"ab-106-itraconazole","phase":"phase_1","mechanism":"Inhibits fungal cytochrome P450 14α-demethylase","indications":["Fungal infections"],"catalyst":""},{"name":"AB-106, digoxin","genericName":"AB-106, digoxin","slug":"ab-106-digoxin","phase":"phase_1","mechanism":"Digoxin inhibits the sodium-potassium ATPase pump.","indications":["Atrial fibrillation","Heart failure"],"catalyst":""},{"name":"NUV-1511","genericName":"NUV-1511","slug":"nuv-1511","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBPaW9ob0Jib2hsd1kteDVzZWpudnBSR1JaR0dIUVozTzFfRV82T2g1LTl1WkFNcUpHQXF2S3ZKMWNCc2FfZi1QSWdCbmxpOV9Cd3AtbWE4UXptQllDQkJB?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill","headline":"NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZE00cGtxR1hOcFpKWnNReEtXb2RWU1huWERpbG5WTE11M3Jyd2d6SHpoUFRSb21CZEJpNHJyNGQ0SUhpVkZJU25ZbHZuczBEZUhGd1ZDcUtIdWdGdWVqdUJRM3IwTzBUOWpJQTBycE9lNjBJWks2MEhsR3F0bHJ1Mkc1d2x3bzVxZzh2Y1FrdlU2enlFdUhNejBVMUJpTkJNYmtaRnpoQVV5R0M5dmtOSE02RWxhMWdBYkRtNDZSNG44SXpRR0hleHFFQWdYTWtzeFJHaQ?oc=5","date":"2026-03-29","type":"regulatory","source":"BioPharma APAC","summary":"Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC","headline":"Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQMzBQWkVnTW4zdW9CTHB6LTBWWVJPQWtiSDZKZmttT0dwNERxRDVuLThhbmdBRm5pNVdEcHJCYjN0bXdwOWo1UzFHVmRqM202Y2llTlNzeVpRS0dFYzNObm42SDVzenBOX2F5Z2NCdzhqQnB2ei1iOW1ld29FTGF1bk5FRjdXcGllSjl6RkJfQ3hGVUJOWUdaY0w5ZGlIYUZwMjlQWnZTOVlGRmtqUTFvWXNRWk01MDhzdnI5VUtTSkxhTzRwYTRLcGxIZjFXRUxpMVBxSGV4bDhzeHdHb0VKYnlxaDkwVVhVaFhIYTNlTUw0OVNFNGRNWERacUhXNVFSYldoeE0tVTJXbUxFTjhRdWh5eDFvemwyOUFOQWxXX1NNMlNEVVpqeXpkZ2QyQllRTVlTQkpwNkNzQkdCMFlKZFp1cXMxTnVDVlE?oc=5","date":"2026-03-26","type":"pipeline","source":"Investing News Network","summary":"Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency ","headline":"Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOVWppOWg4dlJOUERycmRGOU1tS080Y2FTZVp3WWZSWnhVbWJjMjFXRHVIMm4ybUZqbkp6ZFllSXNQM0NNcFBHc0lMYkpRRmNmZ2xMMDRiQjB4cVdHY2J2SUhSSkpOVE1JY3lYcW5kYjJRWlJ2S2JqVFpaUXpKeEdrdFBvSnFRY0V6NDlKX0JrcGxUdXJqRVVlTkZjRkYwMFFtUTlidFVEZ28xVzhheURCSnVnWHUyVVAyNWkyV2FIdHd1WEw2LTZnRXFVZ3F0cmhIRlg1T0dsZk1Vdkd6ZWc?oc=5","date":"2026-03-02","type":"earnings","source":"Investing News Network","summary":"Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 - Investing News Network","headline":"Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcWo0Q0p4NjFUWTBEbFRJYVQ3WDFzLUJxcGt2b3N3MFBjWkdSVDdQcEwwM3BwTUROZGxUczdNNVBBTDRnRTdpUC0zVUZySFpwSUs4c3VMZzBLWlA2eWJhdWlGZDRiNzMwMFhxZFhxWmdPMjJVc3lZN3RkX2ZNRjBTSWE1cUFieVNlSWNnZmlkNHFBdDB2c09zQzcxYWZSNk1jeC1GdkRPVQ?oc=5","date":"2026-01-16","type":"deal","source":"The Pharma Letter","summary":"Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter","headline":"Eisai and Nuvation Bio ink licensing deal for taletrectinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQbU1rRDlZc0tMUzltaXBEZFZuRWc0V2dJcHY3dkZrSXZxaFpGVkxBeWpya1U0X2lCUWVnQnpTdVc4aFN0Y2xsaGI5ZXlMSV9oN1N2RGdtR0d2ak5EVlFqZkI5d2x1a1dtM1U4YjJlcklFQ3NNZTRQTk8yYjdJajJaem1nQzFqcmRCbVpxYThnMWsyMHhRclk3RmxrMVhXMFRlYXpSdE45S2N1UnlRY3NfUFpYSHRLcnVYMjJ0c0hyQW1FTnJOSHhoS05qSDBCaXk1OVdsdGF1R0tLd3JiTW1SejlJV2xZaVczWlAzTWNOWTJfY2NTZkl6RThDemlFaG9Bb3Zhc3h3M0h1SXkwdWIxSlh3?oc=5","date":"2026-01-12","type":"pipeline","source":"BioSpace","summary":"Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - BioSpace","headline":"Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPaklRdGxQMnVJWWh4cnZ0Wjd6N18xZzE3bmNYN3NDdlRLLThxZC13T1QzQVY1MVF0SHRQOEp0NFVJRlZNSGpUVmpHWncySE5hbE5aWHN1YUFPUHZpZElzZTZKcGFHUGJqVWQ2c241clpnblk3MlRwclprOFEwMWt0RWotN2JlSVBtaFhCdWZVUXlGdEVKTFE?oc=5","date":"2025-09-05","type":"regulatory","source":"Mugglehead Magazine","summary":"Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug - Mugglehead Magazine","headline":"Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE02cUVMb2FqZkg0aU5Tdm8xVW1nYU5RVW9FaVJDeVo5YVJXcS1XZFI1ak1hUWNxT2xoMUc2a2hmbzdSNkRYOXg2SzFMSmdZeGl3bjF0OEVmazlRVXROREJRdzJiZkFaY0k?oc=5","date":"2025-08-26","type":"pipeline","source":"Anton Health","summary":"Limited Distribution Updates - Anton Health","headline":"Limited Distribution Updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-06","type":"pipeline","source":"simplywall.st","summary":"Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st","headline":"Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQWEVNcVlPUjgyZ200UF9UcUdoam1qZ0IwMm1lOWpCWjJIWXVudWxqQ08zRUtvV1NqcjkxNnNCXzhabDItdWNfVWtwQXpDalFDeThwc3V4M0FCcDNzSm80Y1dKaGhTWUdKdGJxOENkLXotb3VZQnBPanktR3NjdHZQRWpMMXVrZXhsVGlhQkp3Ni1zcm5zYVBNYTRJbjNNQnRrRlYzSVNEVXQ1NVFPczk5bV9iSTFoZkJqb1ZCSmhn?oc=5","date":"2025-06-11","type":"regulatory","source":"reuters.com","summary":"US FDA approves Nuvation Bio's rare lung cancer drug - reuters.com","headline":"US FDA approves Nuvation Bio's rare lung cancer drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNTHJ6TVRBc3JmN0lNU1VXZnVldF9LQ19tWkVVbEF5bnhQeWR6NHJiQzFid2NhQ2tCVnFjOXhxM0piSWhuRHFIZFVxdTU0S0w4enlhcG9YREVPckZxYkVRd0lNcGZNUU8xd25Tdk9VVXJGNGVvUXVRQUtWeEZLQWZiOWtjbUFnRE9HWXVDUk4yZk9FQi0ycEZsZUoxckhXeHBHZEVEaVdWdnlWQWVQZ0RvOHFTcFhJZ2pnLUo4SUlmR1l0Z2cwS2t3?oc=5","date":"2025-06-11","type":"regulatory","source":"Fierce Pharma","summary":"David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field - Fierce Pharma","headline":"David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field","sentiment":"positive"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":1,"phase_1":5},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}